AC Immune SA Book/Share
What is the Book/Share of AC Immune SA?
The Book/Share of AC Immune SA is 3.56
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on NASDAQ compared to AC Immune SA
What does AC Immune SA do?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Companies with book/share similar to AC Immune SA
- Lumos Pharma Inc has Book/Share of 3.55
- Sandstorm Gold Ltd has Book/Share of 3.55
- CanSino Biologics has Book/Share of 3.55
- Omega Flex Inc has Book/Share of 3.55
- Deltic Plc has Book/Share of 3.55
- Clean TeQ has Book/Share of 3.56
- AC Immune SA has Book/Share of 3.56
- Airgain Inc has Book/Share of 3.56
- Etteplan Oyj has Book/Share of 3.56
- Betterware de Mexico, S.A.P.I. de C.V has Book/Share of 3.56
- Nintendo Co has Book/Share of 3.56
- Hung Hing Printing has Book/Share of 3.57
- Sapmer SA has Book/Share of 3.57